Next report date
Report period
Q1 2024
EPS estimate
−0.02USD
Revenue estimate
23.48 MUSD
−0.07USD
−4.94 MUSD
83.57 MUSD
44.68 M
About ChromaDex Corporation
Sector
CEO
Robert N. Fried
Headquarters
Los Angeles
Website
Employees (FY)
106
Founded
1999
FIGI
BBG000BG1J71
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CDXC is 3.40 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ChromaDex Corporation stocks are traded under the ticker CDXC.
ChromaDex Corporation is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
CDXC stock is 8.31% volatile and has beta coefficient of 1.34. Check out the list of the most volatile stocks — is ChromaDex Corporation there?
CDXC earnings for the last quarter are 0.00 USD per share, whereas the estimation was −0.03 USD resulting in a 116.28% surprise. The estimated earnings for the next quarter are −0.02 USD per share. See more details about ChromaDex Corporation earnings.
ChromaDex Corporation revenue for the last quarter amounts to 19.50 M USD despite the estimated figure of 20.30 M USD. In the next quarter revenue is expected to reach 20.81 M USD.
Yes, you can track ChromaDex Corporation financials in yearly and quarterly reports right on TradingView.
CDXC stock has fallen by 15.00% compared to the previous week, the month change is a 5.82% fall, over the last year ChromaDex Corporation has showed a 150.00% increase.
CDXC net income for the last quarter is 114.00 K USD, while the quarter before that showed −959.00 K USD of net income which accounts for 111.89% change. Track more ChromaDex Corporation financial stats to get the full picture.
Today ChromaDex Corporation has the market capitalization of 256.05 M, it has decreased by 25.13% over the last week.
No, CDXC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CDXC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ChromaDex Corporation stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 106.00 employees. See our rating of the largest employees — is ChromaDex Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ChromaDex Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ChromaDex Corporation stock shows the buy signal. See more of ChromaDex Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ChromaDex Corporation future price: according to them, CDXC price has a max estimate of 7.00 USD and a min estimate of 6.00 USD. Read a more detailed ChromaDex Corporation forecast: see what analysts think of ChromaDex Corporation and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ChromaDex Corporation EBITDA is −1.59 M USD, and current EBITDA margin is −0.23%. See more stats in ChromaDex Corporation financial statements.